Decline in invasive pneumococcal disease after the introduction of protein-polysaccharide conjugate vaccine - PubMed (original) (raw)
. 2003 May 1;348(18):1737-46.
doi: 10.1056/NEJMoa022823.
Monica M Farley, James Hadler, Lee H Harrison, Nancy M Bennett, Ruth Lynfield, Arthur Reingold, Paul R Cieslak, Tamara Pilishvili, Delois Jackson, Richard R Facklam, James H Jorgensen, Anne Schuchat; Active Bacterial Core Surveillance of the Emerging Infections Program Network
Affiliations
- PMID: 12724479
- DOI: 10.1056/NEJMoa022823
Free article
Decline in invasive pneumococcal disease after the introduction of protein-polysaccharide conjugate vaccine
Cynthia G Whitney et al. N Engl J Med. 2003.
Free article
Abstract
Background: In early 2000, a protein-polysaccharide conjugate vaccine targeting seven pneumococcal serotypes was licensed in the United States for use in young children.
Methods: We examined population-based data from the Active Bacterial Core Surveillance of the Centers for Disease Control and Prevention to evaluate changes in the burden of invasive disease, defined by isolation of Streptococcus pneumoniae from a normally sterile site. Serotyping and susceptibility testing of isolates were performed. We assessed trends using data from seven geographic areas with continuous participation from 1998 through 2001 (population, 16 million).
Results: The rate of invasive disease dropped from an average of 24.3 cases per 100,000 persons in 1998 and 1999 to 17.3 per 100,000 in 2001. The largest decline was in children under two years of age. In this group, the rate of disease was 69 percent lower in 2001 than the base-line rate (59.0 cases per 100,000 vs. 188.0 per 100,000, P<0.001); the rate of disease caused by vaccine and vaccine-related serotypes declined by 78 percent (P<0.001) and 50 percent (P<0.001), respectively. Disease rates also fell for adults; as compared with base line, the rate of disease in 2001 was 32 percent lower for adults 20 to 39 years of age (7.6 cases per 100,000 vs. 11.2 per 100,000, P<0.001), 8 percent lower for those 40 to 64 years of age (19.7 per 100,000 vs. 21.5 per 100,000, P=0.03), and 18 percent lower for those 65 years of age or more (49.5 per 100,000 vs. 60.1 per 100,000, P<0.001). The rate of disease caused by strains that were not susceptible to penicillin was 35 percent lower in 2001 than in 1999 (4.1 cases per 100,000 vs. 6.3 per 100,000, P<0.001).
Conclusions: The use of the pneumococcal conjugate vaccine is preventing disease in young children, for whom the vaccine is indicated, and may be reducing the rate of disease in adults. The vaccine provides an effective new tool for reducing disease caused by drug-resistant strains.
Copyright 2003 Massachusetts Medical Society
Comment in
- The conjugate vaccine and invasive pneumococcal disease.
Fedson DS. Fedson DS. N Engl J Med. 2003 Aug 14;349(7):714-6; author reply 714-6. doi: 10.1056/NEJMc035363. N Engl J Med. 2003. PMID: 12917316 No abstract available. - The conjugate vaccine and invasive pneumococcal disease.
Konradsen HB, Nokleby H. Konradsen HB, et al. N Engl J Med. 2003 Aug 14;349(7):714-6; author reply 714-6. N Engl J Med. 2003. PMID: 12921091 No abstract available.
Similar articles
- Herd immunity and pneumococcal conjugate vaccine: a quantitative model.
Haber M, Barskey A, Baughman W, Barker L, Whitney CG, Shaw KM, Orenstein W, Stephens DS. Haber M, et al. Vaccine. 2007 Jul 20;25(29):5390-8. doi: 10.1016/j.vaccine.2007.04.088. Epub 2007 May 22. Vaccine. 2007. PMID: 17583392 - Effect of introduction of the pneumococcal conjugate vaccine on drug-resistant Streptococcus pneumoniae.
Kyaw MH, Lynfield R, Schaffner W, Craig AS, Hadler J, Reingold A, Thomas AR, Harrison LH, Bennett NM, Farley MM, Facklam RR, Jorgensen JH, Besser J, Zell ER, Schuchat A, Whitney CG; Active Bacterial Core Surveillance of the Emerging Infections Program Network. Kyaw MH, et al. N Engl J Med. 2006 Apr 6;354(14):1455-63. doi: 10.1056/NEJMoa051642. N Engl J Med. 2006. PMID: 16598044 - Geographic variation in invasive pneumococcal disease following pneumococcal conjugate vaccine introduction in the United States.
Rosen JB, Thomas AR, Lexau CA, Reingold A, Hadler JL, Harrison LH, Bennett NM, Schaffner W, Farley MM, Beall BW, Moore MR; CDC Emerging Infections Program Network. Rosen JB, et al. Clin Infect Dis. 2011 Jul 15;53(2):137-43. doi: 10.1093/cid/cir326. Clin Infect Dis. 2011. PMID: 21690620 - Management of antibiotic-resistant Streptococcus pneumoniae infections and the use of pneumococcal conjugate vaccines.
Picazo JJ. Picazo JJ. Clin Microbiol Infect. 2009 Apr;15 Suppl 3:4-6. doi: 10.1111/j.1469-0691.2009.02723.x. Clin Microbiol Infect. 2009. PMID: 19366362 Review.
Cited by
- Implications of Cross-Reactivity and Cross-Protection for Pneumococcal Vaccine Development.
Feemster K, Hausdorff WP, Banniettis N, Platt H, Velentgas P, Esteves-Jaramillo A, Burton RL, Nahm MH, Buchwald UK. Feemster K, et al. Vaccines (Basel). 2024 Aug 28;12(9):974. doi: 10.3390/vaccines12090974. Vaccines (Basel). 2024. PMID: 39340006 Free PMC article. Review. - Impact of pneumococcal conjugate vaccines on invasive pneumococcal disease-causing lineages among South African children.
Lekhuleni C, Ndlangisa K, Gladstone RA, Chochua S, Metcalf BJ, Li Y, Kleynhans J, de Gouveia L, Hazelhurst S, Ferreira ADS, Skosana H, Walaza S, Quan V, Meiring S, Hawkins PA, McGee L, Bentley SD, Cohen C, Lo SW, von Gottberg A, du Plessis M. Lekhuleni C, et al. Nat Commun. 2024 Sep 27;15(1):8401. doi: 10.1038/s41467-024-52459-3. Nat Commun. 2024. PMID: 39333488 Free PMC article. - Vaccine-induced strain replacement: theory and real-life implications.
Mahroum N, Karaoglan BS, Ulucam ES, Shoenfeld Y. Mahroum N, et al. Future Microbiol. 2024;19(11):1017-1026. doi: 10.1080/17460913.2024.2345003. Epub 2024 Jun 24. Future Microbiol. 2024. PMID: 38913745 Review. - Opportunities and challenges for T cell-based influenza vaccines.
Mosmann TR, McMichael AJ, LeVert A, McCauley JW, Almond JW. Mosmann TR, et al. Nat Rev Immunol. 2024 Oct;24(10):736-752. doi: 10.1038/s41577-024-01030-8. Epub 2024 May 2. Nat Rev Immunol. 2024. PMID: 38698082 Review. - Necrotizing Pneumonia With Extensive Lobar Cavitation.
Suleac M, Naranjo S, Djassi M, Lavadinho I. Suleac M, et al. Cureus. 2024 Mar 19;16(3):e56437. doi: 10.7759/cureus.56437. eCollection 2024 Mar. Cureus. 2024. PMID: 38638719 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical